Title:
SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/017444
Kind Code:
A1
Abstract:
a compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treating an SHP2 mediation disease. The compound of formula I exerts an effect by means of participating in the regulation of multiple processes such as cell proliferation, apoptosis, migration, and angiogenesis.
More Like This:
Inventors:
WU HAO (CN)
WU WENMAO (CN)
LI LING (CN)
ZHANG ZHAN (CN)
WANG FENG (CN)
YUAN DING (CN)
WU YUNFEI (CN)
CHEN QIANG (CN)
HAN HAN (CN)
GUO JING (CN)
LAN HONG (CN)
DING LIEMING (CN)
WANG JIABING (CN)
WU WENMAO (CN)
LI LING (CN)
ZHANG ZHAN (CN)
WANG FENG (CN)
YUAN DING (CN)
WU YUNFEI (CN)
CHEN QIANG (CN)
HAN HAN (CN)
GUO JING (CN)
LAN HONG (CN)
DING LIEMING (CN)
WANG JIABING (CN)
Application Number:
PCT/CN2021/107808
Publication Date:
January 27, 2022
Filing Date:
July 22, 2021
Export Citation:
Assignee:
BETTA PHARMACEUTICALS CO LTD (CN)
International Classes:
C07D401/14; A61K31/497; A61P35/00; A61P35/02; C07D413/14; C07D471/20; C07D487/04; C07D491/10; C07D513/10
Domestic Patent References:
| WO2019183367A1 | 2019-09-26 | |||
| WO2020063760A1 | 2020-04-02 | |||
| WO2019118909A1 | 2019-06-20 | |||
| WO2019183367A1 | 2019-09-26 |
Foreign References:
| CN105916845A | 2016-08-31 | |||
| CN110143949A | 2019-08-20 |
Other References:
CHAN R J ET AL.: "PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase", BLOOD, vol. 109, 2007, pages 862 - 867
DANCE M ET AL.: "The molecular functions of SHP2 in the RAS/mitogen-activated protein kinase (ERK1/2) pathway", CELL SIGNAL, vol. 20, 2008, pages 453 - 459, XP022425189, DOI: 10.1016/j.cellsig.2007.10.002
TARTAGLIA M ET AL.: "Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan sydrome", NAT GENET, vol. 29, 2001, pages 465 - 468
TARTAGLIA M ET AL., NAT GENET, vol. 34, 2003, pages 148 - 150
LOH ML ET AL., BLOOD, vol. 103, 2004, pages 2325 - 2331
TARTAGLIA M ET AL., BR J HAEMATOL, vol. 129, 2005, pages 333 - 339
XU R ET AL., BLOOD, vol. 106, 2005, pages 3142 - 3149
TANG CHUNLAN ET AL., CHINESE JOURNAL OF LUNG CANCER, vol. 13, 2010, pages 98 - 101
HIGUCHI M ET AL., CANCER SCI, vol. 95, 2004, pages 442 - 447
BENTIRES-ALJ M ET AL., CANCER RES, vol. 64, 2004, pages 8816 - 8820
MARTINELLI S ET AL., CANCER GENET CYTOGENET, vol. 166, 2006, pages 124 - 129
"Design of Prodrugs", 1985, ELSEVIER
DANCE M ET AL.: "The molecular functions of SHP2 in the RAS/mitogen-activated protein kinase (ERK1/2) pathway", CELL SIGNAL, vol. 20, 2008, pages 453 - 459, XP022425189, DOI: 10.1016/j.cellsig.2007.10.002
TARTAGLIA M ET AL.: "Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan sydrome", NAT GENET, vol. 29, 2001, pages 465 - 468
TARTAGLIA M ET AL., NAT GENET, vol. 34, 2003, pages 148 - 150
LOH ML ET AL., BLOOD, vol. 103, 2004, pages 2325 - 2331
TARTAGLIA M ET AL., BR J HAEMATOL, vol. 129, 2005, pages 333 - 339
XU R ET AL., BLOOD, vol. 106, 2005, pages 3142 - 3149
TANG CHUNLAN ET AL., CHINESE JOURNAL OF LUNG CANCER, vol. 13, 2010, pages 98 - 101
HIGUCHI M ET AL., CANCER SCI, vol. 95, 2004, pages 442 - 447
BENTIRES-ALJ M ET AL., CANCER RES, vol. 64, 2004, pages 8816 - 8820
MARTINELLI S ET AL., CANCER GENET CYTOGENET, vol. 166, 2006, pages 124 - 129
"Design of Prodrugs", 1985, ELSEVIER
Download PDF: